J H Frederik Falkenburg
Overview
Explore the profile of J H Frederik Falkenburg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
194
Citations
3750
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wachsmann T, Poortvliet T, Meeuwsen M, Remst D, Toes M, Wouters A, et al.
Mol Ther
. 2025 Mar;
PMID: 40022447
Antigen escape can compromise the efficacy of chimeric antigen receptor- (CAR-) or T cell receptor- (TCR-) engineered T cells. Targeting multiple antigens can effectively limit antigen escape, and combining CAR-with...
2.
Fuchs K, Thomaidou S, van der Slik A, van de Meent M, t Hoen P, Falkenburg J, et al.
Mol Ther Methods Clin Dev
. 2025 Jan;
33(1):101391.
PMID: 39811688
T cell-based immunotherapies targeting antigens on tumor cells have shown efficacy as anti-cancer treatments. While neoantigens are created by somatic mutations acquired during tumorigenesis, allogeneic stem cell transplantation as treatment...
3.
Fuchs K, Goransson M, Kester M, Ettienne N, van de Meent M, de Jong R, et al.
J Immunother Cancer
. 2024 Dec;
12(12).
PMID: 39653555
Allogeneic stem cell transplantation (alloSCT) provides a curative treatment option for hematological malignancies. After HLA-matched alloSCT, donor-derived T cells recognize minor histocompatibility antigens (MiHAs), which are polymorphic peptides presented by...
4.
Falkenburg J, Heemskerk M
Blood
. 2024 Sep;
144(10):1031-1033.
PMID: 39235801
No abstract available.
5.
Fuchs K, Falkenburg J, Griffioen M
Best Pract Res Clin Haematol
. 2024 Aug;
37(2):101555.
PMID: 39098803
Allogeneic hematopoietic cell transplantation (alloHCT) provides a potential curative treatment for haematological malignancies. The therapeutic Graft-versus-Leukaemia (GvL) effect is induced by donor T cells attacking patient hematopoietic (malignant) cells. However,...
6.
Struckman N, de Jong R, Honders M, Smith S, van der Lee D, Koutsoumpli G, et al.
Biomedicines
. 2024 May;
12(5).
PMID: 38791049
DNA methyltransferase 3A () and isocitrate dehydrogenase 1 and 2 () are genes involved in epigenetic regulation, each mutated in 7-23% of patients with acute myeloid leukemia. Here, we investigated...
7.
van Hees E, Morton L, Remst D, Wouters A, Van den Eynde A, Falkenburg J, et al.
Front Immunol
. 2024 May;
15:1368290.
PMID: 38690288
Background: NK cells can be genetically engineered to express a transgenic T-cell receptor (TCR). This approach offers an alternative strategy to target heterogenous tumors, as NK:TCR cells can eradicate both...
8.
Koster E, von dem Borne P, van Balen P, Marijt E, Tjon J, Snijders T, et al.
Front Immunol
. 2024 Mar;
15:1335341.
PMID: 38545096
Introduction: Unmodified donor lymphocyte infusions (DLI) after allogeneic stem cell transplantation (alloSCT) can boost the beneficial Graft-versus-Leukemia (GvL) effect but may also induce severe Graft-versus-Host-Disease (GvHD). To improve the balance...
9.
Fuchs K, van de Meent M, Honders M, Khatri I, Kester M, Koster E, et al.
Blood
. 2024 Mar;
143(18):1856-1872.
PMID: 38427583
Allogeneic stem cell transplantation (alloSCT) is a curative treatment for hematological malignancies. After HLA-matched alloSCT, antitumor immunity is caused by donor T cells recognizing polymorphic peptides, designated minor histocompatibility antigens...
10.
Pool E, Kooy-Winkelaar Y, van Unen V, Falkenburg J, Koning F, Heemskerk M, et al.
Front Immunol
. 2023 Dec;
14:1274116.
PMID: 38094307
Idiopathic acquired aplastic anemia (AA) is considered an immune-mediated syndrome of bone marrow failure since approximately 70% of patients respond to immunosuppressive therapy (IST) consisting of a course of anti-thymocyte...